BD Vystra™ Disposable Pen

The BD Vystra™ Disposable Pen is a commercially proven, patient-centric drug delivery solution that supports the needs of pharmaceutical companies and patients alike. With over 175 million units sold since its launch, this autoinjector has earned a strong global footprint, being used in more than 40 countries and integrated into over 10 approved drug therapies.

Since its first regulatory approval over a decade ago, the BD Vystra™ pen has become a reliable platform for the delivery of various medications, particularly in chronic disease management. Its widespread acceptance is supported by comprehensive human factors research, involving over 250 participants across eight studies—including formative, comparative, patient acceptance, and summative evaluations. These studies confirm the pen’s usability, safety, and patient preference, highlighting its effectiveness in enhancing user confidence and treatment adherence.

More than 25 pharmaceutical companies are currently developing new combination products using the BD Vystra™ platform. The pen offers over 14 preconfigured options to accommodate different drug molecules, concentrations, and therapeutic needs, minimizing the need for device customization and streamlining time-to-market.

Designed with regulatory readiness in mind, the BD Vystra™ Disposable Pen supports the development and commercialization of combination products by providing technical documentation and integration with BD’s existing drug delivery solutions. This platform not only addresses pharmaceutical partners’ performance and scalability needs but also helps improve the patient experience with an intuitive, safe, and effective self-injection device.